What you’ll learn from this webinar
With the cost of a single protocol amendment being as high as $500K per amendments, and over half being deemed avoidable, this webinar is aimed to equip study organizers and insights on how to leverage data and save millions through pre-empting these protocol amendments.
Joined by guest speakers from Bayer, Dr. Silke Strommenger, Head of Trial Feasibility & Analytics, and Sven Oechsner, Head of Feasibility Intelligence, we cover how to leverage patient, investigator, expert and performance data to build better study protocol.
More specifically, this webinar covers:
- Why we need Feasibility, with increasing protocol complexity and amendments
- Who are the key stakeholder groups (investigator, independent experts, patients, external vendors)
- Previous feasibility findings with real use cases from Clariness and Bayer
- Open Q&A with guests